{"abstract":"The National Heart, Lung, and Blood Institute (\"NHLBI\"), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to T-Cure Bioscience, Inc. located in Thousand Oaks, California and incorporated under the laws of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/11/29/2017-25743.html","cfr_references":[],"citation":"82 FR 56622","comment_url":null,"comments_close_on":"2017-12-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before December 14, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2017-25743","effective_on":null,"end_page":56623,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/11/29/2017-25743.xml","html_url":"https://www.federalregister.gov/documents/2017/11/29/2017-25743/prospective-grant-of-exclusive-patent-license-t-cells-transduced-with-hla-a11-restricted-ct-rcc","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2017-25743?publication_date=2017-11-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-11-29/2017-25743/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":225,"last_updated":"2026-08-23 18:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25743.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2017-25743.pdf?1511876731","publication_date":"2017-11-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/11/29/2017-25743.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:14:54Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":56622,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: T-Cells Transduced with HLA A11 Restricted CT-RCC HERV-E Reactive T-Cell Receptors for the Treatment of Renal Cell Carcinoma","toc_doc":"T-Cells Transduced with HLA A11 Restricted CT-RCC HERV-E Reactive T-Cell Receptors for Treatment of Renal Cell Carcinoma","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}